Add as a preferred source on GooglePathos AI Raises $237 Million in Series E at About a $3 Billion Valuation
Bristol Myers Squibb led the round. Pathos AI plans to expand Foundry and advance four cancer drug candidates in clinical development.
Pathos AI has secured $237 million in new financing, giving the drug developer resources to grow its AI platform and move four cancer drug candidates through clinical development.
The Series E put the company’s post-money valuation at about $3 billion. Bristol Myers Squibb was the lead backer, with prior investors participating as well.
Pathos AI plans to use the funding to expand Foundry, its platform for applying thousands of AI agents to drug development. The company also intends to advance four cancer drug candidates that are already in clinical development.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.